country

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

KDR - kinase insert domain receptor Gene

Also Known as flk-1

Species: Canis lupus familiaris (sub-species: familiaris)

Gene Type: protein coding

Gene ID: 482154

About KDR

Primary_assembly 13: 48,053,595-48,095,437 reverse strand.ROS_Cfam_1.0:CM025112.1

This gene has 4 transcripts (splice variants), 199 orthologues and 54 paralogues.

KDR Products (1)

mRNA	Protein	Name
NM_001048024.1	NP_001041489.1	vascular endothelial growth factor receptor 2 precursor

KDR Protein Structure

IgI_VEGFR

IgI_VEGFR-2

IG_like

I-set

VEGFR-2_TMD

PTKc_VEGFR2

0
300
600
900
1200
1355 a.a.

Protein Preferred Names	Protein Names
vascular endothelial growth factor receptor 2	VEGFR2 kinase insert domain receptor (a type III receptor tyrosine kinase)

Related Agents

Approval
Clinical Phase
Pre-clinical Phase

Approval

Bioactive Molecules (6)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-10260	Vandetanib		99.85%	Yes
HY-112306	Ripretinib		98.90%	Yes
HY-14914	Azilsartan		99.68%	Unkown
HY-10330A	Toceranib phosphate	Inhibitor	99.23%	Unkown
HY-10260B	Vandetanib hydrochloride		/	Unkown
HY-10260A	Vandetanib trifluoroacetate		/	Unkown

Clinical Phase

Bioactive Molecules (14)

Cat. No.	Product Name	Effect	Purity	Phase
HY-50751	Linifanib		99.39%	Phase 3
HY-10205	Cediranib		99.87%	Phase 3
HY-10203	Vatalanib	Inhibitor	99.93%	Phase 3
HY-12018	Vatalanib dihydrochloride		99.68%	Phase 3
HY-13049	Cediranib maleate		99.95%	Phase 3
HY-12018A	Vatalanib hydrochloride	Inhibitor	/	Phase 3
HY-110272	Vatalanib succinate	Inhibitor	/	Phase 3
HY-10374	Semaxinib	Inhibitor	99.92%	Phase 2
HY-13024	Rebastinib		99.84%	Phase 2
HY-10338	Foretinib	Inhibitor	99.45%	Phase 2
HY-10987A	ENMD-2076		99.99%	Phase 2
HY-10987	ENMD-2076 Tartrate		99.66%	Phase 2
HY-10204	OSI-930		98.33%	Phase 1
HY-100315	XL 999	Inhibitor	99.01%	Phase 1

Bioactive MoleculesInhibitory Antibodies (2)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P99768	Olinvacimab	Inhibitor	95.00%	Phase 2
HY-P991419	MSB-0254	Inhibitor	/	Phase 1

Pre-clinical Phase

Bioactive Molecules (59)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-12299	WH-4-023	Inhibitor	99.87%	Unkown
HY-151361	AMPK-IN-3	Inhibitor	98.51%	Unkown
HY-W062835	CGP77675	Inhibitor	99.46%	Unkown
HY-10330	Toceranib	Inhibitor	97.41%	Unkown
HY-144707	AK-778-XXMU		99.96%	Unkown
HY-P1663	ATWLPPR Peptide	Inhibitor	99.63%	Unkown
HY-18302	c-Kit-IN-5-1	Inhibitor	98.03%	Unkown
HY-W002616	5-Bromoindolin-2-one		99.50%	Unkown
HY-13838	PLX647	Inhibitor	99.74%	Unkown
HY-15814	HG-7-85-01		98.14%	Unkown
HY-13785	ZM 306416	Inhibitor	99.80%	Unkown
HY-P5438	Srctide	Substrate	99.71%	Unkown
HY-101219	VEGFR-IN-1	Inhibitor	99.07%	Unkown
HY-125741	GW768505A free base	Inhibitor	99.26%	Unkown
HY-10517A	(Z)-Orantinib	Inhibitor	99.44%	Unkown
HY-15769	WHI-P180	Inhibitor	99.84%	Unkown
HY-132135	(1E)-CFI-400437 dihydrochloride	Inhibitor	98.08%	Unkown
HY-133551	WF-47-JS03	Inhibitor	99.63%	Unkown
HY-119757	Tyrphostin AG1433	Inhibitor	99.08%	Unkown
HY-RS07226	KDR Human Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-148742	RET-IN-21	Inhibitor	97.00%	Unkown
HY-RS07227	Kdr Mouse Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-118105	RK-20448	Inhibitor	99.38%	Unkown
HY-50751G	Linifanib (GMP)	Inhibitor	/	Unkown
HY-100824	PP2 Analog	Inhibitor	/	Unkown
HY-10260S	Vandetanib-d6		/	Unkown
HY-10260S1	Vandetanib-d4		/	Unkown
HY-10260S2	Vandetanib-13C6		/	Unkown
HY-10330S	Toceranib-d8	Inhibitor	99.08%	Unkown
HY-116190	CFI-401870	Inhibitor	/	Unkown
HY-117733	Zerumin A	Inhibitor	/	Unkown
HY-120214	TAS05567	Inhibitor	/	Unkown
HY-123586	L-783277	Inhibitor	/	Unkown
HY-13838A	PLX647 dihydrochloride	Inhibitor	/	Unkown
HY-146369	PROTAC VEGFR-2 degrader-2	Degrader	/	Unkown
HY-14979	ML786	Inhibitor	/	Unkown
HY-14979A	ML786 dihydrochloride	Inhibitor	/	Unkown
HY-15334	CEP-5214	Inhibitor	/	Unkown
HY-168114	Multi-kinase inhibitor 3	Inhibitor	/	Unkown
HY-168115	Multi-kinase inhibitor 4	Inhibitor	/	Unkown
HY-172487	DSPE-PEG1000-K237		/	Unkown
HY-172488	DSPE-PEG2000-K237		/	Unkown
HY-172488A	DSPE-PEG3400-K237		/	Unkown
HY-172489	DSPE-PEG5000-K237		/	Unkown
HY-175477	UNC9750	Inhibitor	/	Unkown
HY-18318	Takeda-6D	Inhibitor	99.41%	Unkown
HY-18692	Multi-kinase-IN-12	Inhibitor	/	Unkown
HY-N16797	Sanggenol C		/	Unkown
HY-RS07228	Kdr Rat Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-W062835A	CGP77675 hydrate	Inhibitor	/	Unkown
HY-W701071	Vatalanib-d4		/	Unkown
HY-110045	ZM-306416 hydrochloride	Inhibitor	/	Unkown
HY-119757A	Tyrphostin AG1433 hydrochloride	Inhibitor	/	Unkown
HY-149451	SYHA1815	Inhibitor	/	Unkown
HY-15769A	WHI-P180 hydrochloride	Inhibitor	/	Unkown
HY-174593	Human KDR mRNA		/	Unkown
HY-183616	VEGFR-2-IN-87	Inhibitor	/	Unkown
HY-N10379	19-epi-Scholaricine		99.14%	Unkown
HY-101628	VEGFR-2-IN-9	Inhibitor	/	Unkown

Bioactive MoleculesInhibitory Antibodies (6)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-P991141	Inlecitug	Ligand	98.62%	Unkown
HY-P991689	Girancitug	Inhibitor	98.80%	Unkown
HY-P990318	Alacizumab	Inhibitor	/	Unkown
HY-P990542	Anti-VEGFR2/KDR/CD309 Antibody	Inhibitor	/	Unkown
HY-P990543	Anti-VEGFR2/KDR/CD309 Antibody (AT001)	Inhibitor	/	Unkown
HY-P991420	UB-925	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	KDR	NCBI	NCBI:3791